<DOC>
	<DOCNO>NCT02376790</DOCNO>
	<brief_summary>The purpose study learn role etanercept alone combination methotrexate disease activity subject psoriatic arthritis . To , etanercept alone compare methotrexate alone combination etanercept methotrexate.This study last approximately 1 year ( 52 week ) individual subject . Subjects randomized 1 3 group . Subjects 1 3 chance receiving etanercept plus methotrexate , etanercept alone methotrexate alone . Neither subject study doctor choose group subject randomize . Subjects take one study medication injection skin second medication take mouth . After first 24 week study , doctor evaluates subject determines condition improve , subject may qualify receive etanercept plus methotrexate .</brief_summary>
	<brief_title>Etanercept Methotrexate Combination Monotherapy Psoriatic Arthritis</brief_title>
	<detailed_description>This multicenter , randomize , double-blind control study evaluate efficacy etanercept plus methotrexate therapy etanercept monotherapy compare methotrexate monotherapy , subject PsA measure proportion subject achieve American College Rheumatology ( ACR ) 20 response Minimal Disease Activity ( MDA ) week 24.The study consist 30-day screening period , 48-week double-blind treatment period 30-day safety follow-up period . Approximately 840 subject randomly assign 1:1:1 ratio one three treatment group ( 280 per group ) : etanercept 50 mg weekly subcutaneous injection plus oral methotrexate 20 mg weekly , etanercept 50 mg weekly subcutaneous injection plus oral placebo methotrexate , oral methotrexate 20 mg weekly plus placebo etanercept . Starting week 24 visit , subject inadequate response provide rescue treatment etanercept plus methotrexate remainder study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Key Subject must diagnosis PsA Classification Criteria Psoriatic Arthritis ( CASPAR ) criterion . Subject ≥ 3 tender ≥ 3 swollen joint screen baseline . Subject active psoriatic skin lesion Subject naïve etanercept biologic treatment PsA Psoriasis . Subject prior use methotrexate PsA . Subject history tuberculosis Subject negative test tuberculosis , hepatitis B C. Subject know history alcoholic hepatitis , nonalcoholic steatohepatitis immunodeficiency syndrome , include Human Immunodeficiency Virus infection . Subject active infection ( include chronic localized infection ) antiinfectives indicate within 4 week prior first dose investigational product . Subject serious infection , define require hospitalization intravenous antiinfectives within 8 week prior first dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Arthritis , Psoriasis</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Enbrel</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Minimal Disease Activity</keyword>
</DOC>